Revolution Medicines, Inc. (RVMD)

Market Cap	19.62B +159.0%
Revenue (ttm)	n/a
Net Income	-1.13B
EPS	-5.95
Shares Out	198.17M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,542,210
Open	96.60
Previous Close	94.86
Day's Range	96.60 - 99.64
52-Week Range	29.17 - 124.49
Beta	1.01
Analysts	Strong Buy
Price Target	116.12 (+17.29%)
Earnings Date	May 6, 2026

About RVMD

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236)...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 13, 2020
• Employees: 883
• Stock Exchange: NASDAQ
• Ticker Symbol: RVMD
• Website: https://www.revmed.com

Analyst Summary

According to 17 analysts, the average rating for RVMD stock is "Strong Buy." The 12-month stock price target is $116.12, which is an increase of 17.29% from the latest price.

Price Target

$116.12

(17.29% upside)

Analyst Consensus: Strong Buy